Mesoblast: FY2025 EPS Estimates for Mesoblast Decreased by Analyst

Mesoblast Limited ( NASDAQ:MESO - Free Report ) - Analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for Mesoblast in a research report issued on Monday, March 31st. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will earn ($0.71) per share for the year, down from their previous forecast of ($0.70). Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Mesoblast's current full-year earnings is ($0.70) per share. A number of other research analysts have also weighed in on MESO. Piper Sandler reiterated an "overweight" rating and issued a $24.00 price objective (up from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Jefferies Financial Group lowered Mesoblast from a "buy" rating to a "hold" rating in a research note on Monday, December 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $18.00. Mesoblast Trading Down 0.7 % NASDAQ MESO opened at $11.82 on Wednesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. The company's 50 day moving average is $15.97 and its 200-day moving average is $13.28. Mesoblast has a 12-month low of $4.60 and a 12-month high of $22.00. Institutional Inflows and Outflows Several large investors have recently bought and sold shares of MESO. R Squared Ltd bought a new position in shares of Mesoblast in the fourth quarter worth $30,000. Barclays PLC purchased a new position in Mesoblast during the fourth quarter worth about $38,000. Lindbrook Capital LLC increased its stake in Mesoblast by 70.9% in the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock worth $43,000 after acquiring an additional 901 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Mesoblast in the 4th quarter valued at about $50,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Mesoblast by 86,566.7% during the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock valued at $51,000 after acquiring an additional 2,597 shares during the last quarter. 1.43% of the stock is owned by institutional investors. About Mesoblast ( Get Free Report ) Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. See Also Five stocks we like better than Mesoblast What is a Stock Market Index and How Do You Use Them? Homebuilders in Freefall: Bargain Opportunity or Falling Knife? Retail Stocks Investing, Explained The 3 Most Talked About Investments on WallStreetBets Right Now How to Calculate Options Profits Analyst Targets Signal More Growth in CrowdStrike Stock Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter .